TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02069704
Drug: Avastin® (bevacizumab, reference product)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active ingredient: Bevacizumab 25 mg/mL (strength: 100 mg/4 mL). 30-minute\* IV infusion (5 mg/kg) every 2 weeks, prior to administration of chemotherapy. Treatment will continue until disease progression, unacceptable toxicity, patient withdraws consent or death (whichever occurs first).~\*The first infusion will be given over 90 minutes. If the first infusion is well tolerated, the second infusion can be given over 60 minutes. If this infusion is well tolerated, subsequent infusions can be given over 30 minutes.~The FOLFOX (any) or FOLFIRI regimen will be chosen as per investigator's criteria based on the hospital standard of care.
Study: NCT03704714
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03704714
Drug: Doxorubicin Hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00777803
Drug: NT 201 (IncobotulinumtoxinA (Xeomin®/Bocouture®))
Approvals — FDA: no, EMA: no, PMDA: no
Description: NT201, also known as IncobotulinumtoxinA (Xeomin®/Bocouture®), active ingredient: Clostridium botulinum neurotoxin type A free from complexing proteins, powder for solution for injection dose, 24 units; one injection session of solution, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl). Of the 0.6 mL total injection volume, an aliquot of 0.15 mL was administered in the procerus muscle, aliquots of 0.125 mL were administered in the medial part of the both corrugator muscles and aliquots of 0.1 mL were administered in the middle part of both corrugator muscles.
Study: NCT00042718
Drug: levofloxacin, azithromycin, amoxicillin/clavulanate
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03500159
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Appearance and weight matched tablets without the active product ingredient
Study: NCT04262154
Drug: GnRH analog
Normalized name: gonadotropin releasing factor analog-diphtheria toxoid conjugate Injectable Solution [Improvest]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any GnRH analog that is commercially available, injectable, and long acting analog of the native LHRH peptide and is administered to subjects via intramuscular injection. For this study, any GnRH analog can be used and thee manufacturer's instructions for dose and frequency should be followed.
Study: NCT00145717
Drug: Plant sterol enriched milk tea
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01710644
Drug: Placebo (Caramel in sterile water)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be taken with meals and snacks for 5 to 7 days
Study: NCT04565847
Drug: Salbutamol 5mg/mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized salbutamol given prior to Mannitol-Induced Cough Challenge
Study: NCT03565861
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous vehicle
Study: NCT03565861
Drug: NP10679
Approvals — FDA: no, EMA: no, PMDA: no
Description: NP10679
Study: NCT00653445
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 40mg
Study: NCT03394729
Drug: Xilytol tablet to limit dental biofilm
Approvals — FDA: no, EMA: no, PMDA: no
Description: The tablets will be offered in an exact number of days of use. Collection of total stimulated saliva and dental biofilm will be performed at the beginning of the study (before tablet consumption) and 7 days after the intervention. Saliva samples from each individual will be collected in separate containers as well as the biofilm samples, both at baseline and after 7 days.
Study: NCT01476098
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: SB-705498 placebo
Study: NCT02111187
Drug: LDE225
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sonidegib was given as an oral drug at 800mg daily for 28 days prior to prostetoctomy
Study: NCT01656733
Drug: Nicotrol Inhaler
Normalized name: Nicotrol Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotrol Inhaler, 1-12 cartridges per day, for 6 weeks with a 6 week taper
Study: NCT01656733
Drug: Placebo Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo inhaler, 1-12 cartridges per day, for 6 weeks with a 6 week taper
Study: NCT00725933
Drug: BIIB028
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion administered twice weekly until disease progression or unacceptable toxicity
Study: NCT04242953
Drug: matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part A: single oral administration~Part C: multiple oral administration (14 day dosing)
Study: NCT00801931
Drug: Phenytoin
Normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fosphenytoin can be administered in D5W or 0.9% sodium chloride to a final concentration ranging from 1.5 to 25 mg PE/ml at a rate of 1-3 mg phenytoin sodium equivalents (PE)/kg/min up to 50-150 mg PE/minute.
Study: NCT00801931
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide should be infused over one hour. The drug can be diluted in D5W, NS, or other solutions (100-250 mL) to a maximum concentration of 20 mg/mL.
Study: NCT02784951
Drug: Freeze dried plasma (LyoPlas)
Normalized name: Freez Eez
Approvals — FDA: no, EMA: no, PMDA: no
Description: (LyoPlas N-w (German Red Cross)
Study: NCT00107380
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00107380
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00697099
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml pre-filled syringe strictly identical in appearance but without active component~Subcutaneous injection
Study: NCT04006145
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo identical in appearance to active drug
Study: NCT05030116
Drug: Shenqu Xiaoshi oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shenqu Xiaoshi oral liquid
Study: NCT02811731
Drug: CKD-330 16/5mg - B
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04244175
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive CVL-865 matched placebo tablet orally BID during the treatment period.
Study: NCT04037111
Drug: drug treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram oxalate tablets should be taken orally once every morning for 2 months, each time 10-20mg
Study: NCT01415531
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-match placebo
Study: NCT00262951
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: administered at a dose of 175 mg/m\^2/day continuous infusion (CI) for 38 days in Cycle 1 and then 500 mg/m\^2 intravenously (IV) each week for 6 weeks followed by a 2 week rest (1 cycle = 8 weeks)in Cycle 2 and 3
Study: NCT03904628
Drug: TG02 capsules oral administration, BIW in every 28d
Approvals — FDA: no, EMA: no, PMDA: no
Description: TG02 capsules150mg oral administration, BIW in every 28d
Study: NCT03191682
Drug: PRL3-ZUMAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: The starting dose will be 0.3 mg/kg, administered Q2 weekly, with the subsequent dose levels being 0.9 mg/kg, 3.0 mg/kg, and 6.0 mg/kg, all administered on a Q2 weekly basis until disease progression. The investigator will monitor each subject for the occurrence of AEs. In event of infusion-related adverse events, the Investigator, in consultation with the PI, may increase the duration of the infusion over a period of up to 24 hours at their discretion. Dosing will continue in a standard 3+3 design for dose escalation.
Study: NCT01364155
Drug: Placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02112942
Drug: IDX21459
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02112942
Drug: Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03904628
Drug: TG02 capsules oral administration, BIW in every 28d
Approvals — FDA: no, EMA: no, PMDA: no
Description: TG02 capsules 200mg oral administration, BIW in every 28d
Study: NCT03904628
Drug: TG02 capsules oral administration, BIW in every 28d
Approvals — FDA: no, EMA: no, PMDA: no
Description: TG02 capsules 250mg oral administration, BIW in every 28d
Study: NCT04254679
Drug: Opioid analgesics
Normalized name: OPIOID ANALGESICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current standard of care in the participating centers Prescription of around-the-clock non-opioid analgesics (acetaminophen and/or NSAIDs/COX-2) and a supply of opioids to be used as a rescue in case of breakthrough pain.~The specific round-the-clock analgesia and rescue opioid regimens will be determined by the patient's primary surgeon considering the surgical procedure, comorbidities and patient's preference.
Study: NCT04686916
Drug: IP2018
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test drug
Study: NCT04686916
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02706899
Drug: Placebo (for 33A)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo supplied in single-use vials matching 33A, IV push every 4 weeks
Study: NCT04254679
Drug: Non-opioid analgesics
Normalized name: Non-opioid analgesics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescription of around-the-clock non-opioid analgesics (acetaminophen alone or combined with NSAIDs/COX-2).~The specific non-opioid analgesia regimens will be determined by the patient's primary surgeon considering the surgical procedure, comorbidities and patient's preference.
Study: NCT00324675
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 tablets per day
Study: NCT00374634
Drug: Standard rFSH dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard rFSH dose was 75 IU/day
Study: NCT04226885
Drug: fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: nebulized fentanyl 2μg/kg body weigh
Study: NCT01580423
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsule identical to aprepitant
Study: NCT03658291
Drug: Sanjin tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sanjin tablets,3 pills /time, 4 times/ day, for 7 days+levofloxacin simulants,0.1g, po bid, for 7 days.
Study: NCT03658291
Drug: Sanjin tablets simulants
Normalized name: Staphylococcus simulans
Approvals — FDA: no, EMA: no, PMDA: no
Description: levofloxacin ,0.1g, po bid, for 7 days+Sanjin tablets simulants,3 pills /time, 4 times/ day, for 7 days.
Study: NCT02800928
Drug: CERC-501
Normalized name: CERCIS SILIQUASTRUM WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: CERC-501
Study: NCT02428361
Drug: Biologically active human fecal material, OpenBiome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fecal microbiota transplant
Study: NCT01177813
Drug: Placebo identical to BI10773 high dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo tablets once daily
Study: NCT01177813
Drug: Placebo identical to BI10773 low dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo tablets once daily
Study: NCT01177813
Drug: BI10773
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 10773 high dose tablets once daily
Study: NCT02716597
Drug: 25% Albumin
Normalized name: Flexbumin 25% Albumin (Human) Solution for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02716597
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00292721
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: celecoxib: loading and maintenance for 6 months
Study: NCT01801735
Drug: Meloxicam Test Capsules
Normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02325557
Drug: ADXS31-142
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADXS31-142 IV infusion
Study: NCT02344004
Drug: LAI (Liposomal Amikacin for Inhalation) 590 mg
Normalized name: laidlomycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: LAI 590 mg QD, administered by inhaling drug product that had been aerosolized in an eFlow nebulizer over approximately 14 minutes.
Study: NCT01748877
Drug: NXN-462
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Study drug is to be self-administered twice each day by the patient. Each day the first dose of study drug should be taken preferably one hour prior to, OR one hour after the first meal (breakfast) of the day. The second and final dose each day should be taken with a glass of water at least one hour after the last meal immediately before retiring to sleep.
Study: NCT01435616
Drug: LY2605541
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00972205
Drug: CBT-1(Registered Trademark)
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CBT-1 500 mg/m\^2 oral dose daily for 7 days in divided doses 3 times a day. Cycle days 1-7, repeated every 21 days. no antacids, H2 blocker, or gastric acid inhibiting agents will be administered within 4 hours before or after each daily dose.
Study: NCT00151580
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18 months oral placebo treatment
Study: NCT01153958
Drug: Colposeptine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colposeptine will be administered transvaginally at a dose of 1 capsule every day for 12 consecutive days
Study: NCT04798703
Drug: ONCOFID-P-B™ (PACLITAXEL-HYALURONIC ACID)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 weekly intravesical instillations of ONCOFID-P-B™ (intensive treatment phase) followed by maintenance phase of the study, during which ONCOFID-P-B™ is furtherly administered once a month for 12 months in patients who achieved a complete response (CR) after the 12 weekly instillations.
Study: NCT01181427
Drug: Cytochrome P450 inhibitor
Normalized name: Cytochrome P450 inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: See arm description
Study: NCT01554254
Drug: TXA127
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300mcg/kg/day, subcutaneous injection for up to 28 days
Study: NCT01868646
Drug: Subetta
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each Subetta tablet contains a mixture of affinity purified polyclonal antibodies to β-subunit of the rINS (6 mg) and antibodies to eNOS (6 mg) in released-active form produced by the patented technology in accordance with the applicable European Pharmacopeia requirements.~Standard therapy of type II diabetes mellitus + Subetta (1 tablet 4 times a day) for 36 weeks.~Subetta: oral administration, per 1 intake - 1 tablet (keep in the mouth until complete dissolution, not at mealtime).
Study: NCT01868646
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (identical to Subetta in shape and taste tablet containing exсipients). Standard therapy of type II diabetes mellitus + Placebo (1 tablet 4 times a day) for 36 weeks.~Placebo: oral administration, per 1 intake - 1 tablet (keep in the mouth until complete dissolution, not at mealtime).
Study: NCT01566253
Drug: Acetaminophen, ketoprofen, morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 0.5g, maximum 4g by day, 48 hours ketoprofen 100 mg, twice a day, 48 hours Morphine 10 mg, maximum 90 mg by day, 36 hours
Study: NCT01566253
Drug: Acetaminophen, ketoprofen,morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 1g/100 ml IV, maximum 4g by 24 hours, 48 hours Ketoprofen IV, maximum 0,2 gram by 24 hours, 48 hours Morphine IV,maximum 60mg by 24 hours, 36 hours.
Study: NCT04621513
Drug: western medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast 4mg 1 tablet HS AVAMYS nasal spray 27.5μg QD
Study: NCT01259336
Drug: treatment in cavitary pulmonary aspergillosis
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-tussive, blood transfusion, surgical resection and bronchial artery embolisation(BAE)
Study: NCT04259944
Drug: CAPOX
Normalized name: Capecitabine and Oxaliplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: DAY 1~* OXA 130 mg/m2 administered as intravenous infusion over 2 hours in 250 mL dextrose 5%~* CAPE 1000 mg/m2 administrated per os twice daily~DAY 2-14~• CAPE 1000 mg/m2 os twice daily~Cycle length is 3 weeks comprising 2 hours of oxaliplatin infusion every 21 days, 14 days of oral capecitabine and 7 days of resting.
Study: NCT04259944
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: DAY 1-14~• CAPE 1250 mg/m2 os twice daily~Cycle length is 3 weeks comprising 14 days of oral capecitabine and 7 days of resting.
Study: NCT04259944
Drug: FOLFIRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day 1:~* IRI, 180 mg/m2 administered as iv infusion over 30-90 minutes in 250 mL dextrose 5%, concurrently (via a Y-connector) with~* LV, 400 mg/m2 administered as an iv infusion over 2 hours, in 250 mL dextrose 5%, followed by~* 5-FU, 400 mg/m2 administered as a bolus injection (iv push administered by hand) and then at 2400 mg/m2 administered as a iv infusion over 46 hours.~Cycle length is 2 weeks comprising approximately 48 hours of infusion and 12 days of rest.
Study: NCT00350480
Drug: Combination Birth Control pills
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01592214
Drug: XF-73 in 2% Klucel gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: XF-73 in a modified 2% Klucel® gel formulation: Part 1, #1: concentration 0.5 mg/g, twice a day in volume 0.3 mL/naris/dose, total dose 0.6 mg; Part 1, #2: 2.0 mg/g concentration, twice a day in volume 0.3 mL/naris/dose, total dose 2.4 mg; Part 2, #1: Concentration 0.5 mg/g, 3 doses 8 hours apart on Day 1, total volume 1.8 ml, total dose 0.9 mg, 2 doses 12 hours apart on Days 2-5, total volume 1.2 ml and total dose 0.6 mg ; Part 2, #2: 2.0 mg/g, 3 doses 8 hours apart on Day 1, total volume 1.8 ml, total dose 3.6 mg, 2 doses 12 hours apart on Days 2-5,total volume 1.2 ml and total dose 2.4 mg.
Study: NCT01592214
Drug: XF-73 in 4% Klucel gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: XF-73 in a 4% Klucel® gel formulation: Part 2 #3: concentration of 0.5 mg/g and volume of 0.3 mL/naris/dose in 3 doses 8 hours apart on Day 1 and 2 doses, 12 hours apart on Days 2 to 5. Total daily volume of 1.8 ml on Day 1 and 1.2 ml on Days 2 to 5; and total daily dose of 0.9 mg on Day 1 and 0.6 mg on Days 2 to 5.
Study: NCT01955811
Drug: Administration of platelet concentrate and taking blood samples
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient with the need of a platelet transfusion, will have 4 intervention points. 1. directly before the start of the transfusion a blood sample will be drawn. 2. Patient receives the platelet transfusion. 3. One hour after the end of transfusion a second blood sample will be drawn. 4. 24 h after the end of the platelet transfusion a further bloos sample will be collected. The first two samples will be (beside blood cell counts) spiked in-vitro with different amounts of Human fibrinogen and blood clotting tests will be performed. The same with the 3. blood sample, but without spiking steps.
Study: NCT02659501
Drug: Bupivacaine with epinephrine
Normalized name: bupivacaine / epinephrine Injection [Sensorcaine with Epinephrine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine, like other local anesthetics reduces the flow of sodium in and out of nerves. This decreases the initiation and transfer of nerve signals in the area in which the drug is injected. This leads first to a loss of sensation of pain, temperature, touch, and deep pressure. This drug is the current standard of care for local, postoperative local anesthesia following breast reconstruction. Epinephrine, a vasoconstrictor, is included in bupivacaine formulations to improve the duration of local anesthesia.
Study: NCT01950260
Drug: Levothyroxine
Normalized name: Levothyroxine
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Early initiation of levothyroxine after radioactive iodine (to start at 4 weeks).
Study: NCT03517033
Drug: Forest Pharmaceuticals Inc.'s Bystolic Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00475397
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02659501
Drug: Hydrocodone/acetaminophen
Normalized name: hydrocodone/acetaminophen 5 mg-500 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocodone acetaminophen is a combination of an opiate pain medication (hydrocodone) and a non-steroidal anti-inflammatory drug (acetaminophen) given orally to patients for moderate post-operative pain.
Study: NCT04496167
Drug: EN3835
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collagenase clostridium histolyticum
Study: NCT04496167
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo comparator
Study: NCT02921022
Drug: PEGPH20
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04160520
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Establish proof of concept that low dose morphine in combination with pramipexole is non-inferior to standard dose morphine with respect to providing analgesia in patients presenting to the ED with pain associated with renal colic.
Study: NCT01071889
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo - only excipients with no API
Study: NCT00816140
Drug: Cravit based triple therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin based triple therapy~LALa regimen: levofloxacin 750mg (levofloxacin500 1.5 tablets) once daily, amoxicillin 1000mg twice daily, lansoprazole 30mg twice daily for 7 days
Study: NCT00816140
Drug: Klaricid based triple therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin based triple therapy~CALa regimen: clarithromycin 500mg twice daily, amoxicillin 1000mg twice daily, and lansoprazole 30mg twice daily for 7 days
Study: NCT01537354
Drug: Curosurf®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial dose is 2.5ml/kg (200 mg/kg phospholipid) administered via endotracheal tube. Subsequent doses if needed are 1.25 mL/kg (100 mg/kg phospholipids).
Study: NCT01537354
Drug: Survanta®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial dose is 4 mL/kg (100 mg/kg phospholipids) administered via endotracheal tube. Subsequent doses if needed are 4 mL/kg (100 mg/kg phospholipids).
Study: NCT01893528
Drug: REGN2009
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03891680
Drug: Botox Injectable Product
Normalized name: Botox Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra articular Botox injection
Study: NCT02967211
Drug: NPH insulin
Normalized name: NPH Insulin, Human 300 UNT per 3 ML Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: solution~Route of administration: subcutaneous